Akebia Therapeutics AKBA Stock
Akebia Therapeutics Price Chart
Akebia Therapeutics AKBA Financial and Trading Overview
| Akebia Therapeutics stock price | 0.97 USD |
| Previous Close | 1.02 USD |
| Open | 1.03 USD |
| Bid | 0.73 USD x 200 |
| Ask | 1.3 USD x 200 |
| Day's Range | 1 - 1.05 USD |
| 52 Week Range | 0.88 - 4.08 USD |
| Volume | 2.75M USD |
| Avg. Volume | 3.51M USD |
| Market Cap | 273.62M USD |
| Beta (5Y Monthly) | 0.354 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.08 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.2 USD |
AKBA Valuation Measures
| Enterprise Value | 308.5M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.368421 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.1773609 |
| Price/Book (mrq) | 10 |
| Enterprise Value/Revenue | 1.327 |
| Enterprise Value/EBITDA | 25.433 |
Trading Information
Akebia Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.354 |
| 52-Week Change | -68.61% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 4.08 USD |
| 52 Week Low | 0.88 USD |
| 50-Day Moving Average | 1.3 USD |
| 200-Day Moving Average | 1.86 USD |
AKBA Share Statistics
| Avg. Volume (3 month) | 3.51M USD |
| Avg. Daily Volume (10-Days) | 6.5M USD |
| Shares Outstanding | 268.26M |
| Float | 262.29M |
| Short Ratio | 7.54 |
| % Held by Insiders | 4.00% |
| % Held by Institutions | 42.11% |
| Shares Short | 26.37M |
| Short % of Float | 9.98% |
| Short % of Shares Outstanding | 9.83% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -8.82% |
| Operating Margin (ttm) | -2.76% |
| Gross Margin | 81.94% |
| EBITDA Margin | 5.21% |
Management Effectiveness
| Return on Assets (ttm) | 2.01% |
| Return on Equity (ttm) | -78.95% |
Income Statement
| Revenue (ttm) | 232.4M USD |
| Revenue Per Share (ttm) | 0.88 USD |
| Quarterly Revenue Growth (yoy) | -6.60% |
| Gross Profit (ttm) | 190.43M USD |
| EBITDA | 12.13M USD |
| Net Income Avi to Common (ttm) | -20511000 USD |
| Diluted EPS (ttm) | -0.08 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 162.64M USD |
| Total Cash Per Share (mrq) | 0.61 USD |
| Total Debt (mrq) | 197.52M USD |
| Total Debt/Equity (mrq) | 721.55 USD |
| Current Ratio (mrq) | 1.4 |
| Book Value Per Share (mrq) | 0.102 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 60.37M USD |
| Levered Free Cash Flow (ttm) | 65.81M USD |
Profile of Akebia Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 245 First Street |
| ZIP | 02142 |
| Phone | 617 871 2098 |
| Website | https://www.akebia.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 194 |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Q&A For Akebia Therapeutics Stock
What is a current AKBA stock price?
Akebia Therapeutics AKBA stock price today per share is 0.97 USD.
How to purchase Akebia Therapeutics stock?
You can buy AKBA shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Akebia Therapeutics?
The stock symbol or ticker of Akebia Therapeutics is AKBA.
Which industry does the Akebia Therapeutics company belong to?
The Akebia Therapeutics industry is Drug Manufacturers - Specialty & Generic.
How many shares does Akebia Therapeutics have in circulation?
The max supply of Akebia Therapeutics shares is 268.26M.
What is Akebia Therapeutics Price to Earnings Ratio (PE Ratio)?
Akebia Therapeutics PE Ratio is now.
What was Akebia Therapeutics earnings per share over the trailing 12 months (TTM)?
Akebia Therapeutics EPS is -0.08 USD over the trailing 12 months.
Which sector does the Akebia Therapeutics company belong to?
The Akebia Therapeutics sector is Healthcare.
Akebia Therapeutics AKBA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 33104.2 USD — |
-0.89
|
— — | 32999.64 USD — | 33445.55 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Biotechnology Total Retu XNBI | 6334.93 USD — |
+1.87
|
— — | 6201.97 USD — | 6337.77 USD — | — - | — — |
- {{ link.label }} {{link}}